FDA approves Lilly Cyramza as monotherapy for hepatocellular cancer patients
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently,The FDA's(http://announced the approval of Eli Lilly'scompany,, http://, as a single-drug treatment for patients with hepatocellular carcinoma (HCC)These patients have been treated with sorafenib and have levels of more than 400 ng/mlAbout Cyramza
Cyramza, developed by Lilly, is an angiovascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGFR2, blocking the binding of this receptor to VEGF-A, C, and D, thereby inhibiting vascular hyperplasiaCyramza has been approved by the FDA for treatment of stomach cancer, non-small cell lung cancer and colorectal cancerThis approval is based on a randomized double-blind, placebo-controlled, multicenter 3 clinicaltrial(http://in 292 patients with advanced HCCThese patients had AFP levels of more than 400 ng/ml and were unable to tolerate sorafenib treatment or continue to progress after receiving sorafenibThe main endpoint of the trial was total survival (OS), which showed that the median OS in patients treated with ramucirumab was 8.5 months and the value of the placebo group was 7.3 months (HR: 0.71; 95% CI: 0.53, 0.95; p-0.020)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
